UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Molecular cancer therapeutics, 2018-07, Vol.17 (7), p.1441-1453

2018

Volltextzugriff (PDF)

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics

Breast cancer research and treatment, 2022-01, Vol.191 (2), p.303-317

2022

Volltextzugriff (PDF)

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

Bioconjugate chemistry, 2011-10, Vol.22 (10), p.1994-2004

2011

Volltextzugriff (PDF)

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities

Molecular therapy, 2021-02, Vol.29 (2), p.555-570

2021

Volltextzugriff (PDF)

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Current drug metabolism, 2012-09, Vol.13 (7), p.901-910

2012

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Clinical pharmacokinetics, 2015-01, Vol.54 (1), p.81-93

2015

Volltextzugriff (PDF)

Pharmacokinetics and ADME characterizations of antibody-drug conjugates

Methods in molecular biology (Clifton, N.J.), 2013-01, Vol.1045, p.117

2013

Volltextzugriff (PDF)

Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice

British journal of pharmacology, 2012-05, Vol.166 (1), p.368-377

2012

Volltextzugriff (PDF)

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

mAbs, 2011-07, Vol.3 (4), p.376-386

2011

Volltextzugriff (PDF)

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)

Clinical cancer research, 2015-01, Vol.21 (1), p.123-133

2015

Volltextzugriff (PDF)

Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics

Pharmacology research & perspectives, 2020-04, Vol.8 (2), p.e00573-n/a

2020

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway

The Journal of biological chemistry, 1999-11, Vol.274 (46), p.33057-33063

1999

Volltextzugriff (PDF)

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

The AAPS journal, 2014-09, Vol.16 (5), p.994-1008

2014

Volltextzugriff (PDF)

Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

Journal of medicinal chemistry, 2014-10, Vol.57 (19), p.7890-7899

2014

Volltextzugriff (PDF)

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic

Regulatory toxicology and pharmacology, 2016-12, Vol.82, p.1-13

2016

Volltextzugriff (PDF)

Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro

The Journal of biological chemistry, 1998-11, Vol.273 (45), p.29979-29985

1998

Volltextzugriff (PDF)

Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates

Bioanalysis, 2015-01, Vol.7 (13), p.1583-1604

2015

Volltextzugriff (PDF)

Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125

Drug metabolism and disposition, 2010-12, Vol.38 (12), p.2309-2319

2010

Volltextzugriff (PDF)

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

Molecular cancer therapeutics, 2009-01, Vol.8 (1), p.75-82

2009

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells

The Journal of biological chemistry, 2001-02, Vol.276 (7), p.5281-5286

2001

Volltextzugriff (PDF)

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice

mAbs, 2014-11, Vol.6 (6), p.1631-1637

2014

Volltextzugriff (PDF)

A case study on Sema3E-Fc aggregation and assay-dependent differences in quantitation

Bioanalysis, 2012-03, Vol.4 (6), p.703-711

2012

Volltextzugriff (PDF)

Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats

Hypertension (Dallas, Tex. 1979), 2002-03, Vol.39 (3), p.815-820

2002

Volltextzugriff (PDF)

Effects of Lovastatin on Trafficking of Cystic Fibrosis Transmembrane Conductance Regulator in Human Tracheal Epithelium (∗)

The Journal of biological chemistry, 1995-10, Vol.270 (42), p.25102-25106

1995

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(23)
Animals
(20)
Female
(11)
Mice
(10)
Biochemistry & Molecular Biology
(9)
Pharmacology & Pharmacy
(9)
Trastuzumab
(8)
Cell Line, Tumor
(7)
Rats
(7)
Tissue Distribution
(7)
Antibodies, Monoclonal, Humanized - Pharmacokinetics
(6)
Mice, Nude
(6)
Antibodies, Monoclonal - Immunology
(5)
Antibodies, Monoclonal - Pharmacokinetics
(5)
Biological And Medical Sciences
(5)
Maytansine - Analogs & Derivatives
(5)
Oncology
(5)
Rats, Sprague-Dawley
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells

Trastuzumab does not bind rat or mouse ErbB2/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics

Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism

Physiologically Based Pharmacokinetic Modeling as a Tool to Predict Drug Interactions for Antibody-Drug Conjugates

Pharmacokinetics and ADME characterizations of antibody-drug conjugates

Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)

Complex formation of anti‐VEGF‐C with VEGF‐C released during blood coagulation resulted in an artifact in its serum pharmacokinetics

Vascular Endothelial Growth Factor Governs Endothelial Nitric-oxide Synthase Expression via a KDR/Flk-1 Receptor and a Protein Kinase C Signaling Pathway

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer

Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering

Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic

Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro

Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates

Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125

In vivo activity of novel capecitabine regimens alone and with bevacizumab and oxaliplatin in colorectal cancer xenograft models

Vascular Endothelial Growth Factor KDR Receptor Signaling Potentiates Tumor Necrosis Factor-induced Tissue Factor Expression in Endothelial Cells

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice

A case study on Sema3E-Fc aggregation and assay-dependent differences in quantitation

Exaggerated Hypotensive Effect of Vascular Endothelial Growth Factor in Spontaneously Hypertensive Rats

Effects of Lovastatin on Trafficking of Cystic Fibrosis Transmembrane Conductance Regulator in Human Tracheal Epithelium (∗)

Aktive Filter

Suchergebnisse filtern